Disappointing paper in the New England Journal of Medicine. It was a small study, but it suggests that at least two of the current crop of anti-viral agents are of little use against this particular virus.
Jeremy
Unfortunately we are still in the dark and have to work with poor data, anecdotal or small poor quality trials, back in the old days. But it is what it is.
Regarding this particular combo I saw some concerns that it might drive an immune reconstitution syndrome, no idea how real the concerns are.
We have possibly remdesivir and chloroquine/hydroxychloroquine with in vitro activity, possibly favipiravir (with some human data but for the milder cases mostly). There might a possible benefit from adding tocilizumab to remdesivir.
None, except maybe hydroxychloroquine, will be easy to come by and in the end we are just in supportive care mode. For those unfamiliar, supportive care means buying your body time to heal, if he can.